Published in Bull NYU Hosp Jt Dis on January 01, 2009
The antifolates. Hematol Oncol Clin North Am (2012) 1.21
Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum (2007) 3.12
Hotel-based medicine. J Rheumatol (2008) 2.04
Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther (2009) 1.87
Physical inactivity in patients with rheumatoid arthritis: data from twenty-one countries in a cross-sectional, international study. Arthritis Rheum (2008) 1.51
Quantitative clinical rheumatology: why is a test for anti-CCP antibodies included in most routine care for rheumatoid arthritis while a HAQ/MDHAQ remains largely a research tool? J Rheumatol (2009) 1.43
Incomplete reporting of recruitment information in clinical trials of biologic agents for the treatment of rheumatoid arthritis: a review. Arthritis Care Res (Hoboken) (2012) 1.41
N-of-1 trial of low-dose methotrexate and/or prednisolone in lieu of anti-CCP, MRI, or ultrasound, as first option in suspected rheumatoid arthritis? J Rheumatol (2007) 1.39
Prospects for disease modification in osteoarthritis. Nat Clin Pract Rheumatol (2006) 1.33
Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study. J Rheumatol (2009) 1.28
Visual analog scales in formats other than a 10 centimeter horizontal line to assess pain and other clinical data. J Rheumatol (2008) 1.27
RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. Arthritis Care Res (Hoboken) (2011) 1.12
Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study. N Engl J Med (2015) 1.11
When is it not ethical to withhold treatment for rheumatoid arthritis? Ann Rheum Dis (2013) 1.07
A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative routine assessment of patient index data (RAPID) scores on a multidimensional health assessment questionnaire (MDHAQ). Best Pract Res Clin Rheumatol (2007) 1.06
A practical guide to scoring a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores in 10-20 seconds for use in standard clinical care, without rulers, calculators, websites or computers. Best Pract Res Clin Rheumatol (2007) 1.04
RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds. Arthritis Care Res (Hoboken) (2010) 1.03
Behcet's Syndrome. Drugs (2012) 1.02
RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin North Am (2009) 1.01
Patient questionnaires in rheumatoid arthritis: advantages and limitations as a quantitative, standardized scientific medical history. Rheum Dis Clin North Am (2009) 1.00
Biologics in development for rheumatoid arthritis: relevance to osteoarthritis. Adv Drug Deliv Rev (2006) 1.00
Behçet's syndrome. Rheum Dis Clin North Am (2013) 0.99
Quantitative measures of rheumatic diseases for clinical research versus standard clinical care: differences, advantages and limitations. Best Pract Res Clin Rheumatol (2007) 0.97
Neoplasms as the leading cause of death among patients with rheumatoid arthritis receiving tumor necrosis factor inhibitors: comment on the article by Simard et al. Arthritis Rheum (2013) 0.95
Reevaluation of the role of duration of morning stiffness in the assessment of rheumatoid arthritis activity. J Rheumatol (2009) 0.93
Patient-driven assessment of disease activity in Behçet's syndrome: cross-cultural adaptation, reliability and validity of the Turkish version of the Behçet's Syndrome Activity Score. Clin Exp Rheumatol (2013) 0.93
Parenteral methotrexate for the treatment of rheumatoid arthritis. Bull Hosp Jt Dis (2013) (2013) 0.92
RAPID3-an index of physical function, pain, and global status as "vital signs" to improve care for people with chronic rheumatic diseases. Bull NYU Hosp Jt Dis (2009) 0.91
Proposed severity and response criteria for Routine Assessment of Patient Index Data (RAPID3): results for categories of disease activity and response criteria in abatacept clinical trials. J Rheumatol (2011) 0.88
Treat-to-target: not as simple as it appears. Clin Exp Rheumatol (2012) 0.88
Racial and ethnic disparities in disease activity in patients with rheumatoid arthritis. Am J Med (2013) 0.87
Utility of the new rheumatoid arthritis 2010 ACR/EULAR classification criteria in routine clinical care. BMJ Open (2012) 0.86
Fatal acute necrotizing eosinophilic myocarditis temporally related to use of adalimumab in a patient with relapsing polychondritis. J Clin Rheumatol (2013) 0.85
Patient self-report RADAI (Rheumatoid Arthritis Disease Activity Index) joint counts on an MDHAQ (Multidimensional Health Assessment Questionnaire) in usual care of consecutive patients with rheumatic diseases other than rheumatoid arthritis. Arthritis Care Res (Hoboken) (2013) 0.83
Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: is it time to update the guidelines? J Rheumatol (2002) 0.83
Differences in clinical manifestations, treatment, and concordance rates with two major sets of criteria for Behçet's syndrome for patients in the US and Japan: data from a large, three-center cohort study. Mod Rheumatol (2012) 0.83
Discordance of global estimates by patients and their physicians in usual care of many rheumatic diseases: association with 5 scores on a Multidimensional Health Assessment Questionnaire (MDHAQ) that are not found on the Health Assessment Questionnaire (HAQ). Arthritis Care Res (Hoboken) (2014) 0.82
Complexities in assessment of rheumatoid arthritis: absence of a single gold standard measure. Rheum Dis Clin North Am (2009) 0.81
Pragmatic and scientific advantages of MDHAQ/ RAPID3 completion by all patients at all visits in routine clinical care. Bull NYU Hosp Jt Dis (2012) 0.81
Treatment of rheumatoid arthritis: strategies for achieving optimal outcomes. Ann Rheum Dis (2010) 0.80
Trial of etanercept and methotrexate with radiographic and patient outcomes two-year clinical and radiographic results: Comment on the article by van der Heijde et al. Arthritis Rheum (2006) 0.80
Radiographic benefit without clinical improvement in infliximab-treated patients with rheumatoid arthritis: comment on the article by Smolen et al. Arthritis Rheum (2005) 0.80
A patient-reported outcome measures-based composite index (RAPID3) for the assessment of disease activity in ankylosing spondylitis. Rheumatol Int (2015) 0.79
Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials. J Rheumatol (2006) 0.79
Beyond RAPID3 - practical use of the MDHAQ to improve doctor-patient communication. Bull NYU Hosp Jt Dis (2010) 0.79
Rheumatoid arthritis: When should we use rituximab to treat RA? Nat Rev Rheumatol (2011) 0.79
Are excellent systematic reviews of clinical trials useful for patient care? Nat Clin Pract Rheumatol (2008) 0.77
Improvement Thresholds for Morning Stiffness Duration in Patients Receiving Delayed- Versus Immediate-Release Prednisone for Rheumatoid Arthritis. Bull Hosp Jt Dis (2013) (2015) 0.77
Tools for monitoring remission in rheumatoid arthritis: any will do, let's just pick one and start measuring. Arthritis Res Ther (2013) 0.77
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 0.77
MDHAQ/RAPID3 can provide a roadmap or agenda for all rheumatology visits when the entire MDHAQ is completed at all patient visits and reviewed by the doctor before the encounter. Bull NYU Hosp Jt Dis (2012) 0.76
Headache in Behçet's syndrome: review of literature and NYU Behçet's syndrome center experience. Curr Pain Headache Rep (2014) 0.76
Abatacept versus other biologics in methotrexate inadequate responders with rheumatoid arthritis: you like tomato and I like tomahto... let's call the whole thing off. Arthritis Res Ther (2012) 0.76
Asymptomatic giant coronary aneurysm in an adolescent with Behcet's syndrome. Pediatr Rheumatol Online J (2012) 0.75
Eligibility of rheumatoid arthritis patients seen in clinical practice for rheumatoid arthritis clinical trials: comment on the article by Sokka and Pincus. Arthritis Rheum (2003) 0.75
Analysis of risk factors and comorbid diseases in the development of thrombosis in patients with anticardiolipin antibodies: comment on the article by Sairam et al. Clin Rheumatol (2003) 0.75
Are we content that risk of cancer is not appreciably increased after tumor necrosis factor inhibitor use? Comment on the article by Solomon et al. Arthritis Rheum (2012) 0.75
Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis. Ann Intern Med (2012) 0.75
Quality control of a medical history: improving accuracy with patient participation, supported by a four-page version of the multidimensional health assessment questionnaire (MDHAQ). Rheum Dis Clin North Am (2009) 0.75
Comment on: Web resources for rare auto-inflammatory diseases: towards a common patient registry. Rheumatology (Oxford) (2009) 0.75
Safety and clinical efficacy of golimumab in the treatment of arthritides. Drug Healthc Patient Saf (2010) 0.75
Use of statistical analysis in open extension studies. J Rheumatol (2006) 0.75
Rheumatoid arthritis: Evidence-based rather than habit-based treatment options. Nat Rev Rheumatol (2012) 0.75
Diagnosis and/or classification of vasculitis: different? Curr Opin Rheumatol (2016) 0.75
Are sample sizes of randomized clinical trials in rheumatoid arthritis too large? Eur J Clin Invest (2014) 0.75
An audit of Behcet's syndrome research: a 10-year survey. J Rheumatol (2010) 0.75
The times they are a changin'. Rheumatology (Oxford) (2013) 0.75
The role of cardiac magnetic resonance imaging in antiphospholipid syndrome. J Rheumatol (2002) 0.75
Complex measures and indices for clinical research compared with simple patient questionnaires to assess function, pain, and global estimates as rheumatology "vital signs" for usual clinical care. Rheum Dis Clin North Am (2009) 0.75
Saving time and improving care with a multidimensional health assessment questionnaire: 10 practical considerations. J Rheumatol (2006) 0.75
An update on vasculitides - lumps and constructs. Curr Opin Rheumatol (2017) 0.75
A mosaic of cells in a patient with systemic lupus erythematosus. J Rheumatol (2002) 0.75
Finger and Wrist Pain in Children Using Game Consoles and Laptops Younger Children and Longer Time Are Associated with Increased Pain. Bull Hosp Jt Dis (2013) (2017) 0.75
Use of Biologic Therapy in Racial Minorities With Rheumatoid Arthritis From 2 US Health Care Systems. J Clin Rheumatol (2017) 0.75
Behcet's syndrome in nonendemic regions. Curr Opin Rheumatol (2017) 0.75
Interleukin-6 inhibition--tolerability profile and clinical implications. Bull NYU Hosp Jt Dis (2007) 0.75
Vasculitis: a brief update. Curr Opin Rheumatol (2016) 0.75
Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy. Arthritis Rheum (2002) 0.75